Pyrimidine Ras Modulators Targeting Allosteric Sites
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, particularly those involving Ras/Raf signaling pathways, face challenges due to the undruggable nature of Ras and the complexity of protein-protein interactions, leading to difficulties in modulating aberrant signaling in cancer cells.
Innovation Solution
A compound represented by Formula (I) or its pharmaceutically acceptable salt, which can allosterically modulate Ras/Raf signaling, is administered to effectively inhibit aberrant signaling in cancer cells, potentially in combination with other cancer therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional approaches are used to target Ras, then the high affinity of GTP for Ras is maintained, but this makes Ras undruggable due to the inability to compete with picomolar affinity GTP binding
Solution Approach 1:
The patent employs an intermediary approach by designing compounds that do not directly compete with GTP binding at the active site, but rather bind to allosteric sites or protein-protein interaction interfaces. This intermediary mechanism allows modulation of Ras signaling without facing the picomolar affinity barrier of direct GTP competition, thereby making Ras 'druggable' through indirect intervention in the signaling pathway.
Solution Approach 2:
The invention segments the Ras signaling pathway into multiple targetable components, focusing on protein-protein interaction interfaces between Ras and its effectors (such as Raf) rather than attempting to directly inhibit the entire pathway. By segmenting the target into specific interaction surfaces, the patent creates opportunities for selective inhibition that avoids the undruggable active site while maintaining therapeutic efficacy.
2Measurement precision
If direct inhibition of Ras-GTP interaction is attempted, then specific targeting is achieved, but the picomolar affinity of GTP prevents effective drug binding
Solution Approach 1:
Instead of attempting to directly inhibit the Ras-GTP interaction at the active site (the conventional approach), the patent inverts the strategy by targeting downstream protein-protein interactions in the signaling cascade, such as the Ras-Raf interface. This inversion allows the drug to achieve effective binding by targeting a different, more accessible site while still achieving specific inhibition of Ras-driven signaling pathways.
Solution Approach 2:
The patent uses an intermediary mechanism where compounds bind to intermediate sites in the signaling pathway, such as allosteric sites on Ras or interaction interfaces with effector proteins. This intermediary binding approach enables the drug to modulate Ras signaling effectiveness without directly competing with the picomolar affinity GTP at the primary binding site, thereby achieving both specificity and drugability.
3Ease of manufacture
If protein-protein interaction interfaces are targeted, then druggability is improved, but the complexity of identifying specific interaction sites increases
Solution Approach 1:
The patent applies local quality by focusing on specific, well-defined protein-protein interaction interfaces within the Ras signaling pathway, such as the Ras-Raf binding interface. Rather than attempting to target the entire complex pathway, the invention identifies and targets specific local interaction surfaces that are amenable to small molecule binding, thereby improving druggability while managing the complexity of target identification through focused structural biology approaches.
Data Source
AI summary
The disclosure provides pyrimidine based derivatives of Formula (I), (I-a), (I-b), (I-c), (I-d), (II), or (III), or salts thereof, for the modulation of Ras/Raf signaling. In another aspect, the present disclosure provides methods for the modulation of Ras/Raf signaling using pyrimidine based derivatives of Formula (I), (I-a), (I-b), (I-c), (I-d), (II), or (III), or salts thereof.